关于本白皮书
本资源涵盖的关键主题
The whitepaper emphasizes the importance of a robust pharmacovigilance Quality Management System (QMS) and a well-maintained Pharmacovigilance System Master File (PSMF) detailing system structure, processes, and responsibilities.
White Paper
Ensuring compliance and quality in Pharmacovigilance
The whitepaper emphasizes the importance of a robust pharmacovigilance QMS and a well-maintained Pharmacovigilance System Master File (PSMF). Download now.
2024年10月14日
Strengthen Your Pharmacovigilance System
QbD Group offers a full range of pharmacovigilance services to ensure your products meet compliance standards while safeguarding patient safety.
继续阅读
更多白皮书
白皮书Innovations in ATMP: State of the Art in 2026
Regulatory Affairs, Quality Assurance2026年6月3日
A comprehensive overview of the state of the art in Advanced Therapy Medicinal Products (ATMPs) as of June 2026 — covering EU regulation, cutting-edge manufacturing, evolving quality standards, and the business strategies shaping the future of gene, cell, and tissue therapies.
阅读更多
白皮书Scaling Pharmacovigilance in Europe
Pharmacovigilance2026年5月21日
As pharma SMEs and biotechs grow, pharmacovigilance systems that once worked well can quickly become a bottleneck. This white paper breaks down how to build a pharmacovigilance (PV) setup that scales with your business, without losing compliance or control.
阅读更多
白皮书Annex 1 Compliance Signals from FDA Warning Letters
Qualification & Validation2026年3月13日
What do 230 FDA warning letters reveal about recurring sterile manufacturing deficiencies? This white paper analyses inspection findings from 2023–2025 and maps them to EU GMP Annex 1 expectations, revealing where manufacturers most frequently fall short of sustainable compliance.
阅读更多